ClinicalTrials.gg
CompletedNCT01317004EPOCUpdated Jun 22, 2015Results posted

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change

A Phase 4 interventional study of Fingolimod and Standard MS DMT in Relapsing Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 17 sites in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-06-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
13th of 19
61 · median 142
Started
2011
with 5 others
Phase 4
14 of 19
none open now
Registered
4th of 19
by date
Lead sponsor
14 of 19
Novartis Pharmaceuticals

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 13th largest by enrollment, is one of 6 that started in 2011, is one of 14 in phase 4, and was the 4th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The purpose of this study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs. DMT standard of care, using the global satisfaction subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM-9).

03

Conditions studied

  • Relapsing Remitting Multiple Sclerosis

Keywords

  • Multiple sclerosis
  • Fingolimod
  • Disease Modifying Therapy
  • TSQM-9
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be diagnosed with relapsing remitting MS (RRMS) as defined by 2005 revised McDonald criteria.
  • Patients who explicitly agree to be assigned to a treatment group that may receive fingolimod or DMT after having been informed about their respective benefits and possible adverse events by the investigator.
  • An Expanded Disability Status Scale (EDSS) score of 0-5.5 inclusive.
  • Must have received continuous treatment with a single approved and indicated MS DMT for a minimum of 6 months prior to the screening visit. Patients must continue with this MS DMT until the randomization visit.
  • Naïve to treatment with fingolimod.

Exclusion criteria

Exclusion Criteria:

  • A manifestation of MS other than those defined in the inclusion criteria.
  • A history of chronic disease of the immune system other than MS or a known immunodeficiency syndrome.
  • History of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  • Patients with uncontrolled diabetes mellitus ( > 7%).
  • Diagnosis of macular edema during Screening Phase.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Fingolimod

    Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period.

    Drug: Fingolimod

  • Active comparator
    Multiple Sclerosis Disease Modifying Treatment (MS DMT)

    Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months.

    Drug: Standard MS DMT

Interventions

  • 0.5 mg/day oral capsule

    Also known as: GILENYA™

  • Interferon beta 1a or interferon beta 1b or Glatiramer Acetate

    Also known as: Avonex®,, Copaxone®,, Rebif®,, Betaferon®,, Extavia®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Patient-reported Treatment Satisfaction

    The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.

    Time frame: baseline, 6 months

Secondary outcomes

  1. Change From Baseline in Patient-reported Activities of Daily Living (ADL)

    The PRIMUS activity measure is a 15-item assessment used to evaluate patient-reported activities of daily living. The PRIMUS activities score was calculated summing the 15 items, after recoding the responses from 1 - 3 to 0 - 2. Therefore, the total score ranged from 0 - 3-, where high scores were indicative of greater function limitation. A negative change from baseline indicates improvement.

    Time frame: baseline, 6 months

  2. Change From Baseline in Patient-reported Fatigue

    The fatigue Severity Scale (FSS) is a 9-item scale used to assess fatigue. The FSS score was calculated summing the 9 items of the questionnaire and dividing by the number of non-missing items (each item is based on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)). A negative change from baseline indicates improvement.

    Time frame: 6 months

  3. Change From Baseline in Patient-Reported Effectiveness and Convenience

    The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.

    Time frame: 6 months

  4. Change From Baseline in Patient-reported Depression

    The Beck Depression Inventory Fast Screen (BDI-FS) is a brief, multiple choice, self reported inventory designed to evaluate depression in patients with medical illness. The BDI-FS score was calculated summing the 7 items of the questionnaire. Each item ranged from 0 (not present) to 3 (severe). The total score ranges from 0-3 (minimal depression), 4-8 (mild depression), 9-12 (moderate depression) and 13-21 (severe depression). A negative change from baseline indicates improvement.

    Time frame: 6 months

  5. Change From Baseline in Patient-reported Health Related Quality of Life (QOL)

    The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, pain, general health, energy/fatigue, social functioning, role limitations due to emotional problems and emotional well-being. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.

    Time frame: 6 months

  6. Physician-reported Clinical Global Impression of Improvement (CGI-I)

    The CGI-I is a rating scale allowing a physician-reported global evaluation of the subject's improvement over time. The Investigator assessed the subject's clinical change relative to the symptoms at baseline on the CGI-I, a seven-point scale, with rating as follows: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse. A lower score and a negative change from baseline indicate improvement.

    Time frame: 6 months

07

Results

Posted Jun 22, 2015

Participant flow

Actual enrollment = 61 because 65 participants were randomized to the study, but only 61 participants received at least one dose of study medication. As such, the participant flow captures the 65 participants randomized and the 61 participants who received drug as the safety set.

Participant flow — Overall Study
MilestoneFingolimodMultiple Sclerosis Disease Modifying Treatment (MS DMT)
Started5114
Safety set5011
Completed475
Not completed49
Withdrew: Withdrawal by subject14
Withdrew: Protocol violation02
Withdrew: Adverse event33

Outcome measures

PrimaryChange From Baseline in Patient-reported Treatment Satisfaction

The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.

Time frame:
baseline, 6 months
Reported as:
Mean · score on a scale
Change From Baseline in Patient-reported Treatment Satisfaction
score on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatment (MS DMT)
Change From Baseline in Patient-reported Treatment Satisfaction19.57 ± 21.005.83 ± 16.47
SecondaryChange From Baseline in Patient-reported Activities of Daily Living (ADL)

The PRIMUS activity measure is a 15-item assessment used to evaluate patient-reported activities of daily living. The PRIMUS activities score was calculated summing the 15 items, after recoding the responses from 1 - 3 to 0 - 2. Therefore, the total score ranged from 0 - 3-, where high scores were indicative of greater function limitation. A negative change from baseline indicates improvement.

Time frame:
baseline, 6 months
Reported as:
Mean · score on a scale
Change From Baseline in Patient-reported Activities of Daily Living (ADL)
score on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatment (MS DMT)
Change From Baseline in Patient-reported Activities of Daily Living (ADL)0.19 ± 2.750.15 ± 1.72
SecondaryChange From Baseline in Patient-reported Fatigue

The fatigue Severity Scale (FSS) is a 9-item scale used to assess fatigue. The FSS score was calculated summing the 9 items of the questionnaire and dividing by the number of non-missing items (each item is based on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)). A negative change from baseline indicates improvement.

Time frame:
6 months
Reported as:
Mean · score on a scale
Change From Baseline in Patient-reported Fatigue
score on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatment (MS DMT)
Change From Baseline in Patient-reported Fatigue-0.18 ± 1.46-0.32 ± 1.21
SecondaryChange From Baseline in Patient-Reported Effectiveness and Convenience

The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.

Time frame:
6 months
Reported as:
Mean · score on a scale
Change From Baseline in Patient-Reported Effectiveness and Convenience
score on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatment (MS DMT)
Effectiveness13.53 ± 28.39-1.67 ± 32.40
Convenience24.64 ± 18.2812.78 ± 25.26
SecondaryChange From Baseline in Patient-reported Depression

The Beck Depression Inventory Fast Screen (BDI-FS) is a brief, multiple choice, self reported inventory designed to evaluate depression in patients with medical illness. The BDI-FS score was calculated summing the 7 items of the questionnaire. Each item ranged from 0 (not present) to 3 (severe). The total score ranges from 0-3 (minimal depression), 4-8 (mild depression), 9-12 (moderate depression) and 13-21 (severe depression). A negative change from baseline indicates improvement.

Time frame:
6 months
Reported as:
Mean · score on a scale
Change From Baseline in Patient-reported Depression
score on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatment (MS DMT)
Change From Baseline in Patient-reported Depression-1.15 ± 3.59-0.12 ± 3.06
SecondaryChange From Baseline in Patient-reported Health Related Quality of Life (QOL)

The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, pain, general health, energy/fatigue, social functioning, role limitations due to emotional problems and emotional well-being. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.

Time frame:
6 months
Reported as:
Mean · score on a scale
Change From Baseline in Patient-reported Health Related Quality of Life (QOL)
score on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatment (MS DMT)
Physical functioning (n=41,9)1.71 ± 23.07-1.11 ± 20.73
Role limitations due to physical health (n=42,9)7.14 ± 37.975.56 ± 27.32
Pain (n=45,9)6.56 ± 24.3214.44 ± 15.25
General health (n=44,8)4.52 ± 19.436.25 ± 14.08
Energy/fatigue (n=43,9)2.33 ± 18.816.48 ± 33.24
Social functioning (n=45,9)7.78 ± 24.906.94 ± 25.85
Role limitations d/t emotional problems (n=45,9)7.04 ± 41.823.70 ± 38.89
Emotional well-being (n=43,9)2.51 ± 16.884.89 ± 28.13
PCS (n=40,8)4.52 ± 18.057.83 ± 15.86
MCS (n=40,8)5.88 ± 18.217.28 ± 24.05
SecondaryPhysician-reported Clinical Global Impression of Improvement (CGI-I)

The CGI-I is a rating scale allowing a physician-reported global evaluation of the subject's improvement over time. The Investigator assessed the subject's clinical change relative to the symptoms at baseline on the CGI-I, a seven-point scale, with rating as follows: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse. A lower score and a negative change from baseline indicate improvement.

Time frame:
6 months
Reported as:
Number · Percentage of participants
Physician-reported Clinical Global Impression of Improvement (CGI-I)
Percentage of participantsFingolimodMultiple Sclerosis Disease Modifying Treatment (MS DMT)
Much improved13.6411.11
Minimally improved36.3611.11
No change47.7366.67
Minimally worse2.2711.11

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod—4/50 (8%)13/50 (26%)
Multiple Sclerosis Disease Modifying Treatment (MS DMT)—1/11 (9.1%)7/11 (63.6%)
Most frequent serious events
Most frequent serious events
EventFingolimodMultiple Sclerosis Disease Modifying Treatment (MS DMT)
Human papilloma virus test positiveInvestigations0/501/11
LymphopeniaBlood and lymphatic system disorders2/500/11
Drug ineffectiveGeneral disorders1/500/11
MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/500/11
Multiple sclerosis relapseNervous system disorders1/500/11
Most frequent other events
Showing 10 of 14
Most frequent other events
EventFingolimodMultiple Sclerosis Disease Modifying Treatment (MS DMT)
LymphopeniaBlood and lymphatic system disorders8/500/11
HyperthyroidismEndocrine disorders0/501/11
Vision blurredEye disorders0/501/11
Abdominal pain upperGastrointestinal disorders0/501/11
NauseaGastrointestinal disorders0/501/11
VomitingGastrointestinal disorders0/501/11
Adverse drug reactionGeneral disorders0/501/11
Influenza like illnessGeneral disorders1/501/11
Injection site reactionGeneral disorders0/501/11
HypertransaminasaemiaHepatobiliary disorders1/501/11

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FingolimodMultiple Sclerosis Disease Modifying Treatment (MS DMT)Total
Mean37.96 ± 8.6935.82 ± 7.2237.57 ± 8.43
Sex: Female, Male
Sex: Female, Male(Participants)FingolimodMultiple Sclerosis Disease Modifying Treatment (MS DMT)Total
Female32840
Male18321
08

Study locations

17 sites
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Ponderano, BI 13900, Italy
  • Novartis Investigative Site
    Caltanissetta, CL 93100, Italy
  • Novartis Investigative Site
    Cuneo, CN 12100, Italy
  • Novartis Investigative Site
    Como, CO 22100, Italy
  • Novartis Investigative Site
    Catania, CT 95122, Italy
  • Novartis Investigative Site
    Foggia, FG 71100, Italy
  • Novartis Investigative Site
    Castelfiorentino, FI 50051, Italy
  • Novartis Investigative Site
    Milano, MI 20122, Italy
  • Novartis Investigative Site
    Milano, MI 20133, Italy
  • Novartis Investigative Site
    San Donato Milanese, MI 20097, Italy
  • Novartis Investigative Site
    Modena, MO 41100, Italy
  • Novartis Investigative Site
    Palermo, PA 90129, Italy
  • Novartis Investigative Site
    Palermo, PA 90146, Italy
  • Novartis Investigative Site
    Pisa, PI 56126, Italy
  • Novartis Investigative Site
    Legnago, VR 37045, Italy
  • Novartis Investigative Site
    Novara, 28100, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2011
First posted
Mar 16, 2011
Start
May 2011
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Results first posted
Jun 22, 2015
Last update
Jun 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01317004
Responsible party
Sponsor
First posted
Mar 16, 2011
Start date
May 2011
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Jun 22, 2015
Last update
Jun 22, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
Renato Turrini, MD
study director · Novartis Farma S.p.A.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion